Download PDF
Planta Med 2013; 79(03/04): 312
DOI: 10.1055/s-0032-1328273
Erratum
Georg Thieme Verlag KG Stuttgart · New York

Pharmacokinetic Evaluation of Visnagin and Ammi visnaga Aqueous Extract after Oral Administration in Rats

Karin G. Haug
1   Department of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville, FL, USA
,
Benjamin Weber
1   Department of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville, FL, USA
,
Guenther Hochhaus
1   Department of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville, FL, USA
,
Veronika Butterweck
1   Department of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville, FL, USA
2   Institute for Pharma Technology, School of Life Sciences, University of Applied Sciences Northwestern Switzerland, Muttenz, Switzerland
› Author Affiliations
Further Information

Publication History

Publication Date:
08 February 2013 (online)

    Permissions and Reprints

Correction to:

Pharmacokinetic Evaluation of Visnagin and Ammi visnaga Aqueous Extract after Oral Administration in RatsPlanta Med 2012; 78(17): 1831-1836
DOI: 10.1055/s-0032-1315393

Erratum for: Pharmacokinetic Evaluation of Visnagin and Ammi visnaga Aqueous Extract after Oral Administration in Rats

Published in Planta Medica 2012; 78 (17): 1831–1836

[Table 1] has been corrected.

Table 1 Results of non-compartmental analysis (median (SD)). VG: visnagin, AVE: Ammi visnaga extract, N: number of subjects, AUClast: AUC over the time interval from zero to last quantifiable time point, AUCinf: AUC over the time interval from zero extrapolated to infinity, Cmax: maximum observed concentration, tmax: time at Cmax, λz: terminal elimination rate constant, t1/2: terminal half-life, AUMClast: AUMC over the time interval from zero to last quantifiable time point, AUMCinf: AUMC over the time interval from zero extrapolated to infinity, MRTlast: mean residence time over the time interval from zero to last quantifiable time point, MRTinf: mean residence time over the time interval from zero extrapolated to infinity, CL/F: clearance uncorrected for oral bioavailability (F), Vz/F: volume of distribution during the terminal phase λz uncorrected for F.

Dosing Group (mg/kg)

2.5

5

10

Compound

VG

AVE

VG

AVE

VG

AVE

N

8

7

8

6

8

5

+ Plasma concentration-time profiles with an extrapolated AUC greater than 50 % were excluded from calculation for those parameters, N = 7, 7, 8, 6, 6, 5
++ Plasma concentration-time profiles with an extrapolated AUMC greater than 50 % were excluded from calculation for those parameters, N = 7, 7, 8, 6, 4, 5

AUClast (mg*h/L)

0.21 (0.29)

2.72 (0.65)

2.45 (2.40)

10.11 (2.66)

9.85 (4.09)

35.42 (11.59)

AUCinf (mg*h/L)+

0.15 (0.33)

2.72 (0.67)

2.45 (2.49)

10.22 (2.49)

10.14 (7.86)

35.67 (11.42)

AUC extrap. (%)+

0.10 (2.37)

0.08 (3.99)

0.05 (4.45)

0.05 (5.22)

6.06 (16.84)

0.71 (1.31)

Cmax (mg/L)

0.17 (0.15)

0.52 (0.15)

0.84 (0.63)

1.38 (0.45)

2.03 (0.85)

3.61 (0.47)

tmax (h)

0.42 (0.36)

1 (1.67)

1 (0.52)

2 (1.86)

1 (0.53)

6 (3.27)

λz (1/h) +

2.46 (0.88)

0.81 (0.21)

1.39 (0.72)

0.67 (0.75)

0.36 (0.94)

0.39 (0.13)

t1/2 (h) +

0.28 (0.45)

0.86 (0.41)

0.50 (0.57)

1.14 (2.88)

1.94 (2.19)

1.77 (0.83)

AUMClast (mg*h2/L)

0.23 (0.56)

10.56 (2.82)

4.89 (5.74)

50.00 (6.43)

29.24 (16.62)

227.8 (110.7)

AUMCinf (mg*h2/L)++

0.10 (0.77)

10.59 (3.55)

4.90 (6.60)

52.00 (19.40)

21.14 (12.17)

235.0 (107.7)

AUMC extrap. (%)++

0.63 (8.19)

0.28 (9.14)

0.16 (12.15)

0.17 (18.75)

7.50 (11.24)

3.06 (3.51)

MRTlast (h)

1.05 (0.55)

3.58 (0.49)

2.37 (0.49)

4.62 (0.77)

3.37 (0.66)

6.43 (1.26)

MRTinf (h)++

1.04 (0.62)

3.58 (0.71)

2.45 (0.59)

4.69 (2.19)

2.84 (0.73)

6.59 (1.16)

CL/F (L/h) +

5.24 (5.47)

0.30 (0.08)

0.65 (0.41)

0.17 (0.04)

0.31 (0.26)

0.10 (0.04)

Vz/F (L) +

1.86 (2.38)

0.41 (0.22)

0.62 (0.33)

0.26 (0.77)

0.86 (0.87)

0.36 (0.25)